E
APLT

Ergoteles’s Applied Therapeutics APLT Stock Holding History

Ergoteles’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-36,524
Closed -$27.8K – 1231
2022
Q4 		$27.8K Sell
36,524
-15,161
-29% -$12K ﹤0.01% 1334
2022
Q3 		$48K Sell
51,685
-34,915
-40% -$41.9K ﹤0.01% 1443
2022
Q2 		$82K Buy
+86,600
New +$142K ﹤0.01% 1531

Other funds holding APLT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Ergoteles's APLT Position: Q1 2023 in Review

Ergoteles sold out of Applied Therapeutics (APLT) in Q1 2023, closing a stake of 36,524 shares — an estimated $27.8K sold.

Ergoteles first reported a position in APLT in Q2 2022 and held it in 3 quarters. The position peaked at $82K in Q2 2022. 36 funds tracked by Wall St. Rank hold APLT as of Q1 2023.

  • Ergoteles reported no remaining Applied Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 36,524 Applied Therapeutics shares in Q1 2023, an estimated $27.8K.
  • Ergoteles first reported a position in Applied Therapeutics in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Applied Therapeutics position peaked at $82K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.